Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29615776 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA4KDM4ECYP1A2CYP2D6 | |
| SCHEMBL2441396 | 0.81 | CHRNB2 (0.68) | CHRNB2CHRNA4KDM4ECYP1A2CYP2D6 | |
| SCHEMBL7411369 | 0.81 | CHRNB2 (0.68) | CHRNB2CHRNA4KDM4ECYP1A2CYP2D6 | |
| SCHEMBL15031431 | 0.81 | CHRNB2 (0.68) | CHRNB2CHRNA4KDM4ECYP1A2CYP2D6 | |
| SCHEMBL4111623 | 0.81 | CHRNB2 (0.68) | CHRNB2CHRNA4KDM4ECYP1A2CYP2D6 | |
| SCHEMBL3224827 | 0.81 | CHRNB2 (0.68) | CHRNB2CHRNA4KDM4ECYP1A2CYP2D6 | |
| SCHEMBL7414932 | 0.81 | CHRNB2 (0.68) | CHRNB2CHRNA4KDM4ECYP1A2CYP2D6 | |
| SCHEMBL7409974 | 0.81 | CHRNB2 (0.68) | CHRNB2CHRNA4KDM4ECYP1A2CYP2D6 | |
| SCHEMBL2437117 | 0.81 | CHRNB2 (0.68) | CHRNB2CHRNA4KDM4ECYP1A2CYP2D6 | |
| SCHEMBL15805078 | 0.81 | CHRNB2 (0.68) | CHRNB2CHRNA4KDM4ECYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240173318-A1 | DRY EYE TREATMENTS | OYSTER POINT PHARMA INC (US) | 2024-05-30 | — | — | US | claimed |
| US-11679103-B2 | Multi-targeting agents for Alzheimer's disease therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-20 | — | — | US | claimed |
| US-12576080-B2 | Use of varenicline for treating ocular conditions | Oyster Point Pharma, Inc. | 2026-03-17 | — | — | US | disclosed |
| US-20250275963-A1 | DRY EYE TREATMENTS | OYSTER POINT PHARMA INC (US) | 2025-09-04 | — | — | US | disclosed |
| US-20250255865-A1 | METHODS OF TREATING OCULAR CONDITIONS | OYSTER POINT PHARMA INC (US) | 2025-08-14 | — | — | US | disclosed |
| US-20250235449-A1 | METHODS OF TREATING OCULAR CONDITIONS | OYSTER POINT PHARMA INC (US) | 2025-07-24 | — | — | US | disclosed |
| EP-3848028-B9 | METHODS OF TREATING OCULAR CONDITIONS | OYSTER POINT PHARMA INC (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-4413974-A2 | METHODS OF TREATING OCULAR CONDITIONS | Oyster Point Pharma, Inc. (US) | 2024-08-14 | — | — | EP | disclosed |
| CN-111956650-B | Methods of treating ocular conditions | 奥伊斯特普安生物制药公司 | 2024-06-04 | — | — | CN | disclosed |
| US-20240173318-A1 | DRY EYE TREATMENTS | OYSTER POINT PHARMA INC (US) | 2024-05-30 | — | — | US | disclosed |
| EP-3848028-B1 | METHODS OF TREATING OCULAR CONDITIONS | OYSTER POINT PHARMA INC (US) | 2024-05-29 | — | — | EP | disclosed |
| US-20160106746-A1 | PHARMACEUTICAL FORMULATIONS FOR TREATING OCULAR CONDITIONS | OYSTER POINT PHARMA INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160106744-A1 | METHODS OF INCREASING TEAR PRODUCTION | OYSTER POINT PHARMA INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160106665-A1 | OCULAR DISCOMFORT | OYSTER POINT PHARMA INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160106745-A1 | DRY EYE TREATMENTS | OYSTER POINT PHARMA INC. | 2016-04-21 | — | — | US | disclosed |
| US-20150366523-A1 | NEURONAL IMAGING AND TREATMENT | TYLERTON INTERNATIONAL HOLDINGS INC. (VG) | 2015-12-24 | — | — | US | disclosed |
| US-20150366523-A1 | NEURONAL IMAGING AND TREATMENT | TYLERTON INTERNATIONAL HOLDINGS INC. (VG) | 2015-12-24 | — | — | US | disclosed |
| WO-2014115152-A1 | NEURONAL IMAGING AND TREATMENT | TYLERTON INTERNATIONAL HOLDINGS INC. (VG) | 2014-07-31 | — | — | WO | disclosed |
| US-8729103-B2 | Silent desensitizers of neuronal nAChR and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2014-05-20 | — | — | US | disclosed |
| WO-2011040574-A1 | METHOD FOR PRODUCING AZETIDINYLMETHOXYPYRIDINE DERIVATIVE AND USE OF AZETIDINYLMETHOXYPYRIDINE DERIVATIVE | 国立大学法人京都大学 (JP) | 2011-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576080-B2 | Use of varenicline for treating ocular conditions | PDE6D, PDE11A, PDE10A | CHRNB2 218/4885CHRNA4 301/4885KDM4E 2278/4885 |
| US-20250235449-A1 | METHODS OF TREATING OCULAR CONDITIONS | CYSLTR2, ASAH2, AQP4 | CHRNB2 396/4885CHRNA4 742/4885KDM4E 4445/4885 |
| US-20160106665-A1 | OCULAR DISCOMFORT | PDE6H, PDE6D, TRPA1 | CHRNB2 1498/4885CHRNA4 2068/4885KDM4E 4751/4885 |
| US-20250275963-A1 | DRY EYE TREATMENTS | PDE6D, CRYAB, ALDH1A2 | CHRNB2 1787/4885CHRNA4 2137/4885KDM4E 4549/4885 |
| US-20240173318-A1 | DRY EYE TREATMENTS | PDE6D, CRYAB, ALDH1A2 | CHRNB2 1787/4885CHRNA4 2137/4885KDM4E 4549/4885 |
| US-20160106744-A1 | METHODS OF INCREASING TEAR PRODUCTION | LIPA, PGA5, UTRN | CHRNB2 2353/4885CHRNA4 3542/4885KDM4E 4828/4885 |
| US-20250255865-A1 | METHODS OF TREATING OCULAR CONDITIONS | CYSLTR2, ASAH2, AQP4 | CHRNB2 396/4885CHRNA4 742/4885KDM4E 4445/4885 |
| US-20160106746-A1 | PHARMACEUTICAL FORMULATIONS FOR TREATING OCULAR CONDITIONS | EYA3, EYA2, LIPA | CHRNB2 2572/4885CHRNA4 3615/4885KDM4E 4379/4885 |
| US-20160106745-A1 | DRY EYE TREATMENTS | PDE6D, CRYAB, ALDH1A2 | CHRNB2 1787/4885CHRNA4 2137/4885KDM4E 4549/4885 |
| US-11679103-B2 | Multi-targeting agents for Alzheimer's disease therapy | BACE2, PSEN2, APP | CHRNB2 83/4885CHRNA4 488/4885KDM4E 3774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.